Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients with stable coronary artery disease

European Journal of Heart Failure

Volumn 12, Issue 3, 2010, Pages 254-259

  Patel, Jeetesh V ^a   Abraheem, Abraheem ^b   Creamer, John ^b   Gunning, Mark ^b   Hughes, Elizabeth A ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

Apo AI; Atheroma score; Ejection fraction; LDL cholesterol; Oxidized LDL

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; AREA UNDER CURVE; CHOLESTEROL, HDL; CONFIDENCE INTERVALS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; ROC CURVE; STATISTICS, NONPARAMETRIC; TRIGLYCERIDES; VENTRICULAR FUNCTION, LEFT;

EID: 77249172155     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp202     Document Type: Article

References (42)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. J Am Med Assoc 1979;241:2035-2038.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-444.
3. Mathers CD, Stein C, Ma Fat M, Rao C, Inoue M, Shibuya K, Tomijima N, Bernard C, Xu H. The Global Burden of Disease 2000 Study (version 2): Methods and Results. Geneva: Global Program on Evidence for Health Policy, World Health Organization; 2002. Discussion Paper 50.http://www.who.int/ infobase IBRef: 19998.
4. Michaud CM, Murray CJ, Bloom BR. Burden of disease-implications for future research. JAMA 2001;285:535-539.
5. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104:2746-2753.
6. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001;104:2855-2864.
7. Durrington P. Dyslipidaemia. Lancet 2003;362:717-731.
8. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl. 5):v1-v5.
9. Kita Chun A, McGee SR. Bedside diagnosis of coronary artery disease: a systematic review. Am J Med 2004;117:334-343.
10. Patel JV, Lim HS, Gunarathne A, Tracey I, Durrington PN, Hughes EA, Lip GY. Ethnic differences in myocardial infarction in patients with hypertension: effects of diabetes mellitus. QJM 2008;101:231-236.
11. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framing-ham Study. JAMA 1986;256:2835-2838.
12. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol 1979;44:53-59.
13. Spencer F, Meyer T, Goldberg RJ, Yarzebski J, Hatton M, Lessard D, Gore JM. Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol 1999;34:1378-1387.
14. Nicod P, Gilpin E, Dittrich H, Chappuis F, Ahnve S, Engler R, Henning H, Ross J Jr. Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction. Am J Cardiol 1988;61:1165-1171.
15. Emanuelsson H, Karlson W, Herlitz J. Characteristics and prognosis of patients with acute myocardial infarction in relation to occurrence of congestive heart failure. Eur Heart J 1994;15:761-768. (Pubitemid 24205965)
16. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray JV, Waagstein F, Wedel H, Wessman P, Wikstrand J; CORONA Study Group. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005;7:1059-1069.
17. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, Coats AJ, Anker SD. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-1940. (Pubitemid 37485568)
18. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216-224.
19. Sniderman AD, Dagenais GR, Cantin B, Despres JP, Lamarche B. High apolipopro-tein B with low high-density lipoprotein cholesterol and normal plasma triglycer-ides and cholesterol. Am J Cardiol 2001;87:792-793.
20. Lamarche B, Tchernof A, Mauriege P. Fasting Insulin and apolipoprotein B levels and low-density lipoprotein particle size as Risk factors for Ischaemic heart disease. JAMA 1998;279:1955-1961.
21. Sniderman AD, Furberg CD, Keech A, Roeters van Lennep JE, Frohlich J, Jungner I, Walldius G. Apolipoprotein versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003;361:777-780.
22. Walldius G, Jungner I, Holmes I, Aastveit AH, Kolar W, Steiner E. High apolipo-protein B, low apolipoprotein A-1, and improvement in prediction of fatal myo-cardial infarction (AMORIS study): a prospective study. Lancet 2001;358: 2026-2033.
23. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, Despres JP. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five year follow-up of men in Quebec Cardiovascular Study. Circulation 1996;94:273-278. (Pubitemid 26266109)
24. Talmud PJ, Hawe E, Miller GJ, Humphries SE. Non-fasting apoB and triglycerides levels as a useful predictor of coronary heart disease risk in middle aged UK men. Arterioscler Thromb Vasc Biol 2002;22:1918-1923.
25. de Graaf J, Hak Lemmers HL, Hectors MP. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein fraction in healthy subjects. Arterioscler Thromb Vasc Biol 1991;11:298-1206
26. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 2008;299:2287-2293.
27. Hulthe J, Fagerberg B. Circulating oxidised LDL is associated with subclinical athero-sclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 20:698-702.
28. Obuchowski NA. Sample size tables for receiver operating characteristic studies. AJR Am J Roentgenol 2000;175:603-608.
29. Zweig MH, Broste SK, Reinhart RA. ROC curve analysis: an example showing the relationships among serum lipid and apolipoprotein concentrations in identifying patients with coronary artery disease. Clin Chem 1992;38:1425-1428.
30. Lowry PJ, Mace PJ, Glover DR, Littler WA. The pattern and severity of coronary artery disease in Asians and whites living in Birmingham. Postgrad Med J 1983;59: 634-635.
31. Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477-484.
32. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W, Atherosclerosis risk in communities study group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipopro-teins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-1113.
33. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-381.
34. van Lennep JE, Westerveld HT, van Lennep HW, Zwinderman AH, Erkelens DW, van der Wall EE. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 20:2408-2413.
35. Drexel H, Aczel S, Marte T, Vonbank A, Saely CH. Factors predicting cardiovascular events in statin-treated diabetic and non-diabetic patients with coronary atherosclerosis. Atherosclerosis 2009. Published online ahead of print 21 August 2009.
36. Patel JV, Sosin M, Lim HS, Chung I, Panja N, Davis RC, Hughes EA, Lip GY. Raised leptin concentrations among South Asian patients with chronic heart failure. Int J Cardiol 2007;122:34-40.
37. Holme I, Strandberg TE, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Larsen ML, Lindahl C, Pedersen TR, Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Congestive heart failure is associated with lipoprotein components in statin-treated patients with coronary heart disease Insights from the Incremental Decrease in End points Through Aggressive Lipid Lowering Trial (IDEAL). Atherosclerosis 2009;205:522-527.
38. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum para-oxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999;19: 330-335.
39. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F, CORONA Study Group. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009
40. Mackness B, Mackness M. High-density lipoprotein: why all the fuss? Ann Clin Biochem 2009;46:5-7.
41. Dhingra R, Sesso HD, Kenchaiah S, Gaziano JM. Differential effects of lipids on the risk of heart failure and coronary heart disease: the Physicians' Health Study. Am Heart J 2008;155:869-875.
42. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006;113:2335-2362.